Speaking at the Associated Industries of Massachusetts annual meeting in the Seaport, Kim offered tips for navigating ...

Shares of pharmaceutical companies fell across the world after US President Donald Trump said he planned to order a cut in US ...

Takeda Pharmaceuticals delivered strong FY2024 results and offers value with a 4.81% yield, despite pressure from Vyvanse ...

TOKYO -- Japanese drugmaker Takeda Pharmaceuticals will invest $30 billion in the U.S. over the next five years, CEO ...

Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.

Takeda will host an investor call on Sunday ... but it is to illustrate that as a global innovative pharmaceutical company, we have a very strong presence in the U.S., which is, by far today ...

Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 ...

By Rachel Cohrs Zhang, Derek Wallbank, and Hadriana Lowenkron President Donald Trump said he plans to order a cut in US ...

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Takeda Pharmaceutical Co. imply an improvement in the company's underlying business. Investors should show ...

Texas grocer H-E-B, along with Kroger, Albertsons and Walgreen Co., is accusing pharmaceutical companies of hurting competition. A recently filed lawsuit alleges Japanese drug maker Takeda ...

The lawsuits pertain to the drug Dexilant, used to treat acid reflux, and Copaxone, an injectable drug that treats a type of ...